Negative Phase III trial casts some doubt on Erbitux's role in first-line colorectal cancer
This article was originally published in Scrip
An independently sponsored European Phase III trial (NORDIC VII) testing Merck KGaA/Lilly/Bristol-Myers Squibb's Erbitux (cetuximab) in first-line, metastatic colorectal cancer (mCRC) has failed to show a survival benefit with the EGFR-targeted monoclonal antibody, not even in the subpopulation of KRAS wild-type patients where a benefit was expected.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.